SLC5A2 and COVID-19: Compared with T2DM patients without COVID-19 infection, patients with COVID-19 were less likely to use metformin (88[64.7%] vs 10[6.2%]; p<0.01), thiazolidinediones (30[22.1%] vs 0[0%]; p<0.01) and SGLT2 (66[48.5%] vs 5[3.2%]; p<0.01) (Table 3).